Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001641172-25-002822
Filing Date
2025-04-04
Accepted
2025-04-04 17:17:58
Documents
20
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 formpre14a.htm   iXBRL PRE 14A 707962
2 formpre14a_001.jpg GRAPHIC 53136
3 formpre14a_002.jpg GRAPHIC 51761
4 proxy_001.jpg GRAPHIC 365319
5 proxy_002.jpg GRAPHIC 298797
  Complete submission text file 0001641172-25-002822.txt   3217883

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE envb-20241231.xsd EX-101.SCH 5338
7 XBRL DEFINITION FILE envb-20241231_def.xml EX-101.DEF 9644
8 XBRL LABEL FILE envb-20241231_lab.xml EX-101.LAB 62495
9 XBRL PRESENTATION FILE envb-20241231_pre.xml EX-101.PRE 44314
22 EXTRACTED XBRL INSTANCE DOCUMENT formpre14a_htm.xml XML 88304
Mailing Address 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES FL 34103
Business Address 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES FL 34103 239-302-1707
Enveric Biosciences, Inc. (Filer) CIK: 0000890821 (see all company filings)

EIN.: 954484725 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-38286 | Film No.: 25815798
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)